https://www.selleckchem.com/products/xl092.html
Emerging carbapenem resistance in Escherichia coli, including sequence type 131 (ST131), threatens therapeutic efficacy. Plazomicin (PLZ), a semisynthetic aminoglycoside approved by the FDA in 2018, overcomes the most common aminoglycoside resistance mechanisms and maintains activity against many carbapenem-intermediate or -resistant (CIR) E. coli strains. To assess plazomicin susceptibility among CIR E. coli in relation to region and multiple bacterial characteristics. We determined broth microdilution MICs for plazomicin and 11 comparat
Like
Comment
Share
